Melanoma m1: Diagnosis and therapy

In Vivo

Volumn 28, Issue 3, 2014, Pages 273-285

  Rastrelli, Marco ^a   Tropea, Saveria ^a   Pigozzo, Jacopo ^a   Bezzon, Elisabetta ^a   Campana, Luca Giovanni ^a   Stramare, Roberto ^b   Alaibac, Mauro ^b   Rossi, Carlo Riccardo ^a,b  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Chemotherapy; Radiotherapy; Review; Stage IV melanoma; Surgery; Tumor doubling time

Indexed keywords

DABRAFENIB; IPILIMUMAB; LACTATE DEHYDROGENASE; TRAMETINIB; VEMURAFENIB;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL PRACTICE; ECHOGRAPHY; HUMAN; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONAL EXPERIENCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; TUMOR GROWTH; MELANOMA; METASTASIS;

HUMANS; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING;

EID: 84918535688     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Review

References (150)

1. Rastrelli M, Alaibac M, Stramare R, Chiarion Sileni V, Montesco MC, Vecchiato A, Campana LG and Rossi CR: Melanoma m (zero): Diagnosis and Therapy. ISRN Dermatol 616170, 2013.
2. Gandini S, Autier P and Boniol M: Reviews on sun exposure and artificial light and melanoma. Prog Biophys Mol Biol 107: 362-366, 2011.
3. Geller AG, Clapp RW, Sober AJ, Gonsalves L, Mueller L, Christiansen CL, Shaikh W and Miller DR: Melanoma epidemic: A n analysis of six decades of Data From the Connecticut Tumor Registry. J Clin Oncol 31: 4172-4178, 2013.
4. Panasiti V, Curzio M, Roberti V, Lieto P, Devirgiliis V, Gobbi S, Naspi A, Coppola R, Lopez T, Di Meo N, Gatti A, Trevisan G, Londei P and Calvieri S: Metastatic volume: A n old oncologic concept and a new prognostic factor for stage iv melanoma patients, Dermatology, 2013 [Epub ahead of print].
5. Gordon R: Skin cancer: A n overview of epidemiology and risk factors. Semin Oncol Nurs 29: 160-169, 2013.
6. Jaimes N and Marghoob AA: An update on risk factors, prognosis and management of melanoma patients. G Ital Dermatol Venereol 147: 1-19, 2012 (in Italian).
7. Trinh VA: Current management of metastatic melanoma. Am J Health Syst Pharm 65: (suppl 9), 3-8 2008.
8. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S and Kirkwood JM: Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26: 527-534, 2008.
9. Weide B, Elsässer M, Büttner P, Pflugfelder A, Leiter U, Eigentler TK, Bauer J, Witte M, Meier F, Garbe C: Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer 107: 422-428, 2012.
10. Tarhini AA, Stuckert J, Lee S, Sander and Kirkwood JM: Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 27: 38-44, 2009.
11. Fernandez-Flores A: Prognostic factors for melanoma progression and metastasis: from hematoxylin-eosin to genetics. Rom J Morphol Embryol 533: 449-459, 2012.
12. Balch CM, Gershenwald JE, Soong SJ, Thompson, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ and Sondak VK: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 527-534, 2009.
13. Balch CM, Soong SJ, Murad TM, Smith JW, Maddox WA and Durant JR: A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1: 126-134, 1983
14. Barth A, Wanek LA and Morton DL: Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181: 193-201, 1995.
15. Batus M, Waheed S, Ruby C, Petersen L, Bines SD and Kaufman HL: Optimal management of metastatic melanoma: current strategies and future directions. Am J Clin Dermatol 14: 179-194, 2013.
16. Hill VK, Gartner JJ, Samuels Y and Goldstein AM: The genetics of melanoma: recent advances. Annu Rev Genomics Hum Genet 14: 257-279, 2013.
17. Damsky WE, Theodosakis N and Bosenberg M: Melanoma metastasis: new concepts and evolving paradigms. Oncogene, 2013 [Epub ahead of print]
18. Leong SP, Gershenwald JE, Soong SJ, Schadendorf D, Tarhini AA, Agarwala S, Hauschild A, Soon CW, Daud A and Kashani-Sabet M: Cutaneous melanoma:Amodel to study cancer metastasis. J Surg Oncol 103: 538-549, 2011.
19. Mohamed A, Gonzalez RS, Lawson D, Wang J and Cohen C: Tumor Stem Cells (CD271, c-kit, SOX10) in Melanomas: Prognostic and Outcome Implications. Appl Immunohistochem Mol Morphol, 2013 [Epub ahead of print].
20. Zimmerer RM, Korn P, Demougin P, Kampmann A, Kokemüller H, Eckardt AM, Gellrich NC and Tavassol F: Functional features of cancer stem cells in melanoma cell lines, Cancer Cell Int 13(1): 78, 2013.
21. Weide B, Elsässer M, Büttner P, Pflugfelder A, Leiter U, Eigentler TK, Bauer J, Witte M, Meier F and Garbe C: Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer 107: 422-428, 2012.
22. Perrotta R, Bevelacqua Y, Malaguarnera G, Paladina I, Giordano M and Malaguarnera M: Serum markers of cutaneous melanoma. Fronti Biosci 2: 1115-1122, 2010.
23. Egberts F, Pollex A, Egberts JH, Kaehler KC, Weichenthal M and Hauschild A: Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH. Onkologie 31: 380-384, 2008.
24. Koyanagi K, Kuo C, Nakagawa T, Mori T, Ueno H, Lorico AR Jr., Wang HJ, Hseuh E, O'Day SJ and Hoon DS: Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem 51: 981-988, 2005.
25. Mohammed MQ, Abraha HD, Sherwood RA, MacRae K and Retsas S: Serum S100β protein as a marker of disease activity in patients with malignant melanoma. Med Oncol 18: 109-120, 2001.
26. Alber B , Hein R , Garbe C, Caroli U and Luppa PB: Multicenter evaluation of the analytical and clinical performance of the Elecsys S100 immunoassay in patients with malignant melanoma. Clin Chem Lab Med 43: 557-563, 2005.
27. Kelley MC, Jones RC, Gupta RK, Yee R, Stern S, Wanek L and Morton DL: Tumor-associated antigen TA-90 immune complex assay predicts subclinical metastasis and survival for patients with early stage melanoma. Cancer 83: 1355-1361, 1998.
28. Itakura E, Huang RR, Wen DR, Paul E, Wünsch PH and Cochran AJ: IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Mod Pathol 24: 801-809, 2011.
29. Facies MB, Gupta RK, Ye X, Lee C, Yee R, Leopoldo Z, Essner R, Foshag LJ, Elashoff D and Morton DL: A Comparison ofthree tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients, Cancer Invest 25: 285-293, 2007.
30. Miliotes G, Lyman GH, Cruse CW, Puleo C, Albertini PA, Rapaport D, Glass F, Fenske N, Soriano T, Cuny C, Van Voorhis N and Reintgen D: Evaluation of new putative tumor markers for melanoma. Ann Surg Oncol 3: 558-563,1996.
31. Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, Ball G, Creaser C, Rees R and Schadendorf D: Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol 23: 5088-5093, 2005.
32. Caron J, Mangé A, Guillot B and Solassol J: Highly sensitive detection of melanoma based on serum proteomic profiling. J Cancer Res Clin Oncol 135: 1257-1264, 2009.
33. Schröer-Günther MA, Wolff RF, Westwood ME, Scheibler FJ, Schürmann C, Baumert BG, Sauerland S and Kleijnen J: F-18- fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: A systematic review. Syst Rev 1: 62, 2012.
34. Tan JC and Chatterton BE: Is there an added clinical value of 'true' whole-body(18)F-FDG PET/CT imaging in patients with malignant melanoma? Hell J Nucl Med 15: 202-205, 2012.
35. Bronstein Y, Ng CS, Rohren E, Ross MI, Lee JE, Cormier J, Johnson VE and Hwu WJ: PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: Evaluation of the additive value after conventional imaging. Am J Roentgenol 198: 902-908, 2012.
36. Wagner T, Chevreau C, Meyer N, Mourey L, Courbon F and Zerdoud S: Routine FDG PET-CT in patients with a high-risk localized melanoma has a high predictive positive value for nodal disease and high negative predictive value for the presence of distant metastases. J Eur Acad Dermatol Venereol 26: 1431-1435, 2012.
37. Peric B, Zagar I, Novakovic S, Zgajnar J and Hocevar M: Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma. BMC Cancer 11: 328, 2011.
38. Mosavi F, Ullenhag G, Ahlström H: Whole-body MRI including diffusion-weighted imaging compared to CT for staging of malignant melanoma. Ups J Med Sci 118: 91-97, 2013
39. Zukauskaite R, Schmidt H, Asmussen JT, Hansen O and Bastholt L: Asymptomatic brain metastases in patients with cutaneous metastatic malignant melanoma. Melanoma Res 23: 21-26, 2013.
40. Tabouret E, Bauchet L and Carpentier AF: Brain metastases epidemiology and biology. Bull Cancer 100: 57-62, 2013.
41. Rubaltelli L, Beltrame V, Scagliori E, Bezzon E, Frigo AC, Rastrelli M and Stramare R: Potential use of contrast-enhanced ultrasound (CEUS) in the detection of metastatic superficial lymph nodes in melanoma patients. Ultraschall Med, 2013 [Epub ahead of print].
42. Schäfer-Hesterberg G, Schoengen A, Sterry W and Voit C: Use of ultrasound to early identify, diagnose and localize metastases in melanoma patients. Expert Rev Anticancer Ther 7: 1707-1716, 2007.
43. Voit CA, Van Akkooi AC, Eggermont AM, Schäfer-Hesterberg G, Kron M, Ulrich J, Sterry W, Schoengen A and Rademaker J: Fine-needle aspiration cytology of palpable and nonpalpable lymph nodes to detect metastatic melanoma. J Natl Cancer Inst 103: 1771-1777, 2011.
44. Schaefer-Hesterberg G, Akkooi AJ, Letsch A, Roewert J, Blume-Peytavi U, Keilholz U and Voit C: Clinically misinterpreted melanoma metastases can correctly be diagnosed by ultrasoundguided fine-needle aspiration cytology. Eur J Dermatol 21: 238-241, 2011.
45. Leung AM, Hari DM and Morton DL: Surgery for distant melanoma metastasis. Cancer J 18: 176-184, 2012.
46. Ollila DW, Gleisner AL, Hsueh EC: Rationale for complete metastasectomy in patients with stage IV metastatic melanoma. J Surg Oncol 104: 420-424, 2011.
47. Caudle AS and Ross MI: Metastasectomy for stage IV melanoma: For whom and how much? Surg Oncol Clin N Am 20: 133-144, 2011.
48. Howard JH, Thompson JF, Mozzillo N, Nieweg OE, Hoekstra HJ, Roses DF, Sondak VK, Reintgen DS, Kashani-Sabet M, Karakousis CP, Coventry BJ, Kraybill WG, Smithers BM, Elashoff R, Stern SL, Cochran AJ, Faries MB and Morton DL: Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol 19: 2547-2555, 2012.
49. Ollila DW: Complete metastasectomy in patients with stage IV metastatic melanoma, Lancet Oncol 7: 919-924, 2006.
50. Martinez SR and Youn SE: A rational surgical approach to the treatment of distant melanoma metastases. Cancer Treat Rev 34: 614-620, 2008.
51. Mosca PJ, Teicher E, Nair SP and Pockaj BA: Can surgeons improve survival in stage IV melanoma? J Surg Oncol 97: 462-468, 2008.
52. Wasif N, Bagaria SP, Ray P and Morton DL: Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol 104: 111-115, 2011.
53. Tauceri F, Mura G, Roseano M, Framarini M, Ridolfi L and Verdecchia GM: Surgery and adjuvant therapies in the treatment of stage IV melanoma: our experience in 84 patients. Langenbecks Arch Surg 394: 1079-1084, 2009
54. Young SE, Martinez SR and Essner R: The role of surgery in treatment of stage IV melanoma. J Surg Oncol 94: 344-351, 2006.
55. Carlson JA: Tumor doubling time of cutaneous melanoma and its metastasis, American Journal of Dermatopathology, vol. 25 no. 4 pp. 291-299, 2003.
56. Ollila DW, Stern SL and Morton DL: Tumor doubling time: a selection factor for pulmonary resection of metastatic melanoma. J Surg Oncol 69: 206-211, 1998.
57. Kähler KC, Egberts F and Gutzmer R: Palliative treatment of skin metastases in dermato-oncology. J Dtsch Dermatol Ges, 2013 [Epub ahead of print]
58. Galeon M, Bassi A, Scarfì F, Arunachalam M and Difonzo EM: Multiple skin metastases of malignant melanoma. QJM, 2013 [Epub ahead of print].
59. Spillane AJ, Pasquali S, Haydu LE, Thompson JF, Patterns of Recurrence and Survival After Lymphadenectomy in Melanoma Patients: Clarifying the Effects of Timing of Surgery and Lymph Node Tumor Burden. Ann Surg Oncol, 2013 [Epub ahead of print].
60. Zdzienicki M, Rutkowski P, Nowecki ZI, van Akkooi AC, Michej W, Dziewirski W, ͆witaj T, Pieńkowski A, Sałamacha M, Bylina E and Eggermont AM: The analysis of the outcomes and factors related to iliac-obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases. Eur J Surg Oncol 39: 304-310, 2013.
61. Shada AL, Walters DM, Tierney SN and Slingluff CL Jr.: Surgical resection for bulky or recurrent axillary metastatic melanoma. J Surg Oncol 105: 21-25, 2012.
62. Badgwell B, Xing Y, Gershenwald JE, Lee JE, Mansfield PF, Ross MI and Cormier JN: Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. Ann Surg Oncol 14: 2867-2875, 2007.
63. Velu PP, Cao C and Yan TD: Current surgical management of melanoma metastases to the lung. J Thor Dis 5(suppl 3): 274-276, 2013.
64. Younes R, Abrao FC and Gross J: Pulmonary metastasectomy for malignant melanoma: prognostic factors for long-term survival, Melanoma Res 23: 307-311, 2013.
65. Lee JH, Gulec SA, Kyshtoobayeva A, Sim MS and Morton DL: Biological factors, tumor growth kinetics, and survival after metastasectomy for pulmonary melanoma. Ann Surg Oncol 16: 2834-2839, 2009.
66. Kidner TB, Yoon J, Faries MB and Morton DL: Preoperative imaging of pulmonary metastases in patients with melanoma: Implications for minimally invasive techniques, Arch Surg 147: 871-874, 2012.
67. Heyman BM, Chung MM, Lark AL and Shofer S: Endobronchial metastasis from primary anorectal melanoma. Am J Case Rep 14: 253-257, 2013.
68. Bouchentouf R, Benjelloun A, Ibtissam Z and Ali Aitbenasser M: Endobronchial metastases of a malignant melanoma of rectal origin: Clinical case and review of the literature. Pan Afr Med J 14: 67, 2013.
69. Jennings BR, Millward MJ, Amanuel B, Mulrennan S, Joosten SA and Phillips MJ: Role of endobronchial ultrasound in diagnosis and molecular assessment of metastatic melanoma, Respirology 17: 991-996, 2012.
70. Teo YK and Kor AC: 'Black bronchoscopy' a case of endobronchial metastases from melanoma. J Bronchology Interv Pulmonol 14: 146-148, 2010.
71. Gorantla V, Kirkwood JM and Tawbi HA: Melanoma brain metastases: An unmet challenge in the era of active therapy, Curr Oncol Rep 15: 483-491, 2013.
72. Bottoni U, Clerico R, Paolino G, Ambrifi M, Corsetti P and Calmieri S: Predictors and survival in patients with melanoma brain metastases. Med Oncol 2013 [Epub ahead of print].
73. Zukauskaite R, Schmidt H, Asmussen JT, Hansen O and Bastholt L: Asymptomatic brain metastases in patients with cutaneous metastatic malignant melanoma. Melanoma Res 23: 21-26, 2013.
74. Ramakrishna N, Margolin KA: Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases. Am Soc Clin Oncol Educ Book 399-403, 2013.
75. Long GV and Margolin KA: Multidisciplinary approach to brain metastasis from melanoma. Am Soc Clin Oncol Educ Book 393-398, 2013.
76. Bafaloukos D and Gogas H: The treatment of brain metastases in melanoma patients. Cancer Treat Rev 30: 515-520, 2004.
77. Nicholas S, Mathios D, Jackson C and Lim M: Metastatic melanoma to the brain: surgery and radiation is still the standard of care. Curr Treat Options Oncol 14: 264-279, 2013.
78. Vaidyanathan S, Mansour P, Hughes PL, Selmi F, Singh G, Pulya K and Soni BM: Challenges in diagnosis and treatment of a cervical spinal cord injury patient with melanoma, adenocarcinoma, and hepatic and osteolytic metastases: need to implement strategies for prevention and early detection of cancer in spinal cord injury patients. Case Rep Oncol Med, 2012: 531214, 2012.
79. Wilson DA, Fusco DJ, Uschold TD, Spetzler RF and Chang SW: Chang, Survival and functional outcome after surgical resection of intramedullary spinal cord metastases. World Neurosurg 77: 370-374, 2012.
80. Hashii H, Mizumoto M, Kanemoto A, Harada H, Asakura H, Hashimoto T, Furutani K, Katagiri H, Nakasu Y and Nishimura T: Radiotherapy for patients with symptomatic intramedullary spinal cord metastasis, J Radiat Res 52: 641-645, 2011.
81. Ishii T, Terao T, Komine K and Abe T: Intramedullary spinal cord metastases of malignant melanoma: an autopsy case report and review of the literature. Clin Neuropathol 29: 334-340, 2010
82. Nishihara M, Sasayama T, Kondoh T, Tanaka K, Kohmura E and Kudo H: Long-term Survival after surgical resection of primary spinal malignant melanoma. Neurol Med Chir 49: 546-548, 2009
83. Liang KV, Sanderson SO, Nowakowski GS and Arora AS: Metastatic malignant melanoma of the gastrointestinal tract. Mayo Clin Proc 81: 511-516, 2006.
84. Retsas S and Christofyllakis C: Melanoma involving the gastrointestinal tract. Anticancer Res 21(2B): 1503-1507, 2001.
85. Vettoretto N, De Cesare V, Cervi E, Villanacci V, Ruzzenenti N and Cervi G: Gastric metastasis from melanoma. Report of 2 surgically treated cases, Minerva Chir 55: 787-791, 2000.
86. Dequanter D, Sales F, Legendre H and Lothaire P: Surgical resection for gastrointestinal metastatic melanoma. Ann Chir, 129: 278-281, 2004.
87. Kasza J, Espinel F, Khambaty F, Bashir S and Brody F: Laparoscopy for stage IV melanoma in two organs. Surg Laparosc Endosc Percutan Tech 20: 295-297, 2010.
88. Góbor L, Czeyda-Pommersheim F and Köves I: Surgical treatment options of metastatic tumours in the gastrointestinal tract (stomach, small and large bowel). Magy Seb 60: 284-288, 2007.
89. Trout AT, Rabinowitz RS, Platt JF and Elsayes KM: Melanoma metastases in the abdomen and pelvis: Frequency and patterns of spread. World J Radiol 5: 25-32, 2013.
90. Rose DM, Essner R, Hughes TM, Tang PC, Bilchik A, Wanek LA, Thompson JF and Morton DL: Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg 136: 950-955, 2001.
91. Ryu SW, Saw R, Scolyer RA, Crawford M, Thompson JF and Sandroussi C: Liver resection for metastatic melanoma: equivalent survival for cutaneous and ocular primaries, J Surg Oncol 108: 129-135, 2013.
92. Aubin JM, Rekman J, Vandenbroucke-Menu F, Lapointe R, Fairfull-Smith RJ, Mimeault R, Balaa FK and Martel G: Systematic review and meta-analysis of liver resection for metastatic melanoma. Br J Surg 100: 1138-1147, 2013.
93. Du SD, Mao YL, Li SH, Sang XT, Lu X, Xu YY, Xu HF, Zhao L, Bai CM, Zhong SX and Huang JF: Surgical resection plus biotherapy/chemotherapy improves survival of hepatic metastatic melanoma. World J Hepatol 4: 305-310, 2012.
94. Bala MM, Riemsma RP, Wolff R and Kleijnen J: Cryotherapy for liver metastases. Cochrane Database Syst Rev, 6:CD009058, 2013.
95. Woon WW, Haghighi KS, Zuckerman RS and Morris DL: Liver resection and cryotherapy for metastatic melanoma. Int Surg 93: 274-277, 2008.
96. Kuvshinoff B and Fong Y: Surgical therapy of liver metastases. Semin Oncol 34: 177-185, 2007.
97. Ozülker T, Ozülker F, Cicin I and Ozpaçac T: A case of malignant melanoma with cardiac and gallbladder metastases detected by FDG PET-CT. Clin Nucl Med 34: 948-949, 2009.
98. MVernadakis S, Rallis G, Danias N, Serafimidis C, Christodoulou E, Troullinakis M, Legakis N and Peros G: Metastatic melanoma of the gallbladder: An unusual clinical presentation of acute cholecystitis. World J Gastroenterol 15: 3434-3436, 2009.
99. Sen CA, Kargi A, Kaya V, Tanriverdi O: Isolated and solitary splenic metastasis detected by positron emission tomography in a patient with malignant melanoma: Case report and review of the literature. Contemp Oncol 17: 214-217, 2013.
100. Finocchi L, Covarelli P, Gentile D, Cattorini L, Cirocchi R, Noya G, Sciannameo FL: Melanoma metastases to the spleen: laparoscopic approach. Minerva Chir 67: 95-96, 2012.
101. Wedin R, Falkenius J, Weiss RJ and Hansson J: Surgical treatment of skeletal metastases in 31 melanoma patients. Acta Orthop Belg 78: 246-253, 2012.
102. Huang KY, Wang CR and Yang RS: Rare clinical experiences for surgical treatment of melanoma with osseous metastases in Taiwan. BMC Musculoskelet Disord 8: 70, 2007.
103. Lau YS, Sabokbar A, Giele H, Cerundolo V, Hofstetter W and Athanasou NA: Malignant melanoma and bone resorption. Br J Cancer 94: 1496-1503, 2006.
104. Gokaslan ZL, Aladag MA and Ellerhorst JA: Melanoma metastatic to the spine: A review of 133 cases. Melanoma Res 10: 78-80, 2000.
105. Stahl S, Santos Stahl A, Lotter O, Pfau M, Perner S and Schaller HE: Palliative surgery for skeletal metastases from melanoma in the scaphoid-a critical case report appraisal. J Plast Reconstr Aesthet Surg 65: 1111-1115, 2012.
106. Judge JM, Tillou JD, Slingluff CL Jr., Kern JA, Kron IL and Weiss GR: Surgical management of the patient with metastatic melanoma to the heart. J Cardiol Surg 28: 124-128, 2013.
107. Pinto F, Cappa E, Brescia A, Sacco E, Volpe A, Totaro A, Gardi M, Pierconti F and Bassi PF: Metastasis to the renal hilum from malignant melanoma of the anterior trunk: An unusual finding. Arch Ital Urol Androl 82: 119-121, 2010.
108. Gakis G, Merseburger AS, Sotlar K, Kuczyk MA, Sievert KD and Stenzl A: Metastasis of malignant melanoma in the ureter: Possible algorithms for a therapeutic approach. Int J Urol 16: 407-409, 2009.
109. Ejaz S, Shawa H, Henderson SA and Habra MA: Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass. BMJ Case Rep, 2013.
110. Gupta D, Neto AG, Deavers MT, Silva EG and Malpica A: Metastatic melanoma to the vagina: Clinicopathologic and immunohistochemical study of three cases and literature review. Int J Gynecol Pathol 22: 136-140, 2003.
111. Fenzl V, Prkacin I and Skrtic A: Malignant melanoma ovarian metastasis mimicking acute tubo-ovarian abscess. Eur J Gynaecol Oncol 32: 582-584, 2011.
112. Simeone S, Laterza MM, Scaravilli G, Capuano S, Serao M, Orabona P, Rossi R and Balbi C: Malignant melanoma metastasizing to the uterus in a patient with atypical postmenopause metrorrhagia. A case report. Minerva Ginecol 61: 77-80, 2009.
113. Kurul S, Aykan F and Tas F: Penile metastasis of cutaneous malignant melanoma: a true hematogenous spread? Case report and review of the literature. Melanoma Res 16: 259-261, 2006.
114. Friedrich RE and Abadi M: Distant metastases and malignant cellular neoplasms encountered in the oral and maxillofacial region: Analysis of 92 patients treated at a single institution. Anticancer Res 30: 1843-1848, 2010.
115. Rosenberg C and Finger PT: Cutaneous malignant melanoma metastatic to the eye, lids, and orbit. Surv ophthalmol 53: 187-202, 2008.
116. Forschner A, Heinrich V, Pflugfelder A, Meier F and Garbe C: The role of radiotherapy in the overall treatment of melanoma. Clin Dermatol 31: 282-289, 2013.
117. Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O and Bentzen SM: Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet 345: 540-543, 1995.
118. Bentzen SM, Overgaard J, Thames HD, Overgaard M, Vejby Hansen P, von der Maase H and Meder J: Clinical radiobiology of malignant melanoma. Radiother Oncol 16: 169-182, 1989.
119. Bentzen SM, Thames HD: Tumor volume and local control probability: Clinical data and radiobiological interpretations. Int J Rad Oncol Biol Phys 36: 247-251, 1996.
120. Rompoti N, Schilling B, Livingstone E, Griewank K, Hillen U, Sauerwein W, Pöttgen C, Stuschke M, Schadendorf D and Zimmer L: Combination of BRAF Inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicity. J Clin Oncol 31: 3844-3845, 2013
121. Gojkovič-Horvat A, Jančar B, Blas M, Zumer B, Karner K, Hočevar M and Strojan P: Adjuvant radiotherapy for palpable melanoma metastases to the groin: When to irradiate? Int J Rad Oncol 83: 310-316, 2011.
122. Majer M and Samlowski WE: Management of metastatic melanoma patients with brain metastases, Curr Oncol Rep 9: 411-416, 2007.
123. Fox MC, Lao CD, Schwartz JL, Frohm ML, Bichakjian CK and Johnson TM: Management options for metastatic melanoma in the era of novel therapies: A primer for the practicing dermatologist: Part II: Management of stage IV disease. J Am Acad Dermatol 68: 13.e1-13, 2013.
124. Carlino MS, Fogarty GB and Long GV: Treatment of melanoma brain metastases: Anew paradigm. Cancer J 18: 208-212, 2012.
125. Meyners T, Heisterkamp C, Kueter JD, Veninga T, Stalpers LJ, Schild SE and Rades D: Prognostic factors for outcomes after whole-brain irradiation of brain metastases from relatively radioresistant tumors: a retrospective analysis. BMC Cancer 10: 582, 2010.
126. Marcou Y, Lindquist C, Adams C, Retsas S and Plowman PN: What is the optimal therapy of brain metastases? Clin Oncol (R Coll Radiol) 13: 105-111, 2001.
127. Thillays F, Doré M and Martin SA: Postoperative brain radiotherapy: Role of stereotactic radiotherapy. Cancer Radiother 17: 407-412, 2013
128. Lippitz B, Lindquist C, Paddick I, Peterson D, O'Neill K and Beaney R: Stereotactic radiosurgery in the treatment of brain metastases: The current evidence. Cancer Treat Rev, 2013 [Epub ahead of print]
129. Rava P, Leonard K, Sioshansi S, Curran B, Wazer DE, Cosgrove GR, Norén G and Hepel JT: Survival among patients with 10 or more brain metastases treated with stereotactic radiosurgery. J Neurosurg 119: 457-462, 2013.
130. Rodrigues G, Gonzalez-Maldonado S, Bauman G, Senan S and Lagerwaard F: A statistical comparison of prognostic index systems for brain metastases after stereotactic radiosurgery or fractionated stereotactic radiation therapy. Clin Oncol (R Coll Radiol) 25: 227-235, 2013.
131. Fokas E, Henzel M, Surber G, Kleinert G, Hamm K and Engenhart-Cabillic R: Stereotactic Radiosurgery and fractionated stereotactic radiotherapy: comparison of efficacy and toxicity in 260 patients with brain metastases. J Neurooncol 109: 91-98, 2012.
132. Kim YJ, Cho KH, Kim JY, Lim YK, Min HS, Lee SH, Kim HJ, Gwak HS, Yoo H and Lee SH: Single-dose versus fractionated stereotactic radiotherapy for brain metastases. Int J Radiat Oncol 81: 483-489, 2011.
133. Ishii T, Terao T, Komine K and Abe T: Intramedullary spinal cord metastases of malignant melanoma: An autopsy case report and review of the literature, Clin Neuropathol 29: 334-340, 2010.
134. Bedane C, Leccia MT, Sassolas B, Bregman B, Lebbé C; French investigators of the MELODY study: Treatment patterns and outcomes in patients with advanced melanoma in France. Curr Med Res Opin 29: 1297-1305, 2013.
135. Tzika E, Moura B, Romano E and Michielin O: New therapeutic weapons in stage IV melanoma. Rev Méd Suisse 9: 1095-1098, 2013.
136. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M and Thatcher N: Randomised phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic melanoma. J Clin Oncol 18: 158-166, 2000.
137. Quirt I, Verma S, Petrella T, Bak K and Charette M: Temozolomide for the treatment of metastatic melanoma: A systematic review. Oncologist 12: 1114-1123, 2007.
138. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A and Menu Y: Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study. J Clin Oncol 22: 1118-1125, 2004.
139. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A and Urba WJ: Improved survival with ipilimumab in patients with metastases with melanoma. N Engl J Med 363: 711-723, 2010.
140. Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr., Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A and Wolchok JD: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526, 2011.
141. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
142. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group: Improved survival with vemurafenib in BRAF V600E mutation with melanoma. N Engl J Med 364: 2507-2516, 2011.
143. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK and Ribas A: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366: 107-114, 2012.
144. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V and Chapman PB: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase III randomised controlled trial, Lancet 380: 358-365, 2012.
145. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367: 107-114, 2012.
146. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, Le NT, Patel K, Lewis: Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with BRAF-mutant metastatic cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 31: 482-489, 2013.
147. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K and Weber J: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367: 1694-1703, 2012.
148. Sznol M, Kluger HM, Hodi FS, McDermott DF, Carvajal RD, Lawrence DP, Topalian SL, Atkins MB, Powderly JD, Sharfman WH, Puzanov I, Smith DC, Wigginton JM, Kollia G, Gupta AK and Sosman JA: Survival and long-term follow-up of safety and response in patients with advanced melanoma in a phase I trial of nivolumab. J Clin Oncol 31, 2013 (suppl; abstr CRA9006)
149. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A and Sznol M: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369: 122-133, 2013 .
150. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP and Ribas A: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369: 134-144, 2013.